provocative testing raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
== Career == In 1967, Chrétien opened a laboratory on polypeptide hormones at the Clinical Research Institute of Montreal (CRIM), where he would remain until 1999. He was an Associate Member, Experimental Medicine at McGill University from 1969 to 1999. In 1999 he was scientific director and CEO of the Loeb Health Research Institute at the Ottawa Civic Hospital. Chrétien was a Professor of Medicine in the Faculty of Medicine at the Université de Montréal from 1975 to 1999. He was Chief of Endocrinology at Hôtel-Dieu de Montréal. In 1998, he was appointed a Professor, Department of Medicine, Faculty of Medicine, University of Ottawa. In 2006, he was appointed Senior Scientist of Hormone, Growth and Development at the Ottawa Health Research Institute. He created Quebec’s first protein chemistry laboratory at IRCM in 1967 and continued to lead influential research programs for decades.
== Genomes == The genome sequencing of the lactic acid bacterium L. plantarum WCFS1 shows more molecular details. The chromosome contains 3,308,274 base pairs (GenBank: AL935263.1). The GC content of L. plantarum is 44.45% with the average protein count 3063. According to the experiment from Wageningen Centre for Food Sciences, the rRNA number of L. plantarum WCFS1 is 15, and the number or tRNA is 70.
An alternative picoinjection method involves utilizing the injection reagent as the conductor of an electric field where a voltage applied to the fluid stimulates injection. Such a method also allows for greater control of injection as the voltage applied corresponds to the volume of reagent fluid injected. Droplet-to-droplet contamination is a challenge of many injection methods. To combat this, Doonan et al. developed a multifunctional K-channel, which flows reagent streams opposite the path of the droplet stream. Utilizing an interface between the two channels, injection is achieved similarly to picoinjection, but any bilateral contamination washed away through continuous reagent flow. Contamination is avoided at the expense of potentially wasting precious reagent.
Sources: en.wikipedia.org
Depyrogenation refers to the removal of pyrogens from solutions, most commonly from injectable pharmaceuticals. A pyrogen is defined as any substance that can cause a fever. Bacterial pyrogens include endotoxins and exotoxins, although many pyrogens are endogenous to the host. Endotoxins include lipopolysaccharide (LPS) molecules found as part of the cell wall of Gram-negative bacteria, and are released upon bacterial cell lysis. Endotoxins may become pyrogenic when released into the bloodstream or other tissue where they are not usually found. Although the colon contains Gram-negative bacteria in abundance, they do not cause a pyrogenic effect as the bacteria are not undergoing gross lysis, and the immune system is not exposed to free endotoxin while the colonic wall is intact. When LPS is released upon bacterial cell lysis, the lipid A component is first bound by serum LPS-Binding Protein (LBP) and then transferred to CD14 (either free CD14 in the serum or bound to the cell surface of macrophages or monocytes). This monomerises the aggregated LPS, as the LPS receptor Toll-like Receptor 4 (TLR4) cannot recognise LPS while aggregated. Monomeric LPS is then transferred to MD-2 pre-complexed with TLR4 on macrophages and monocytes. This leads to release of pro-inflammatory cytokines and nitric oxide, which may lead ultimately to septic shock depending on the strength of response. Vascular endothelial cells also express TLR4 and MD-2 and so respond to LPS directly, as well as via cytokines and nitric oxide.
=== Mark McVeigh Era (2026–present) === On Monday 24th of August 2026, Mark McVeigh was appointed Senior Coach of Essendon, a three year contract running through to the end of the 2029 AFL season. Club President Andrew Welsh said the decision was unanimously supported by the club board, and stating in a press release that "we have been extremely clear on the strategy and direction of this football club. We are building the next successful era for Essendon, with a view to playing finals, winning finals and competing for premierships. Mark is the best coach to take us forward to achieve that."
Hari, Johann (2015). Chasing the Scream: The First and Last Days of the War on Drugs. London; New York: Bloomsbury. ISBN 978-1-62040-890-2. Blanchard, Michael; Chin, Gabriel J. (1998). "Identifying the Enemy in the War on Drugs: A Critique of the Developing Rule Permitting Visual Identification of Indescript White Powders in Narcotics Prosecutions". American University Law Review (47): 557. SSRN 1128945. Daniel Burton-Rose, The Celling of America: An Inside Look at the U.S. Prison Industry. Common Courage Press, 1998. Stephanie R. Bush-Baskette, "The War on Drugs as a War on Black Women", in Meda Chesney-Lind and Lisa Pasko (eds.), Girls, Women, and Crime: Selected Readings. Sage, 2004. Chin, Gabriel (2002). "Race, the War on Drugs and the Collateral Consequences of Criminal Conviction". Gender, Race & Justice (6): 253. SSRN 390109. Alexander Cockburn and Jeffrey St. Clair, Whiteout: The CIA, Drugs and the Press. New York: Verso, 1998. Mitchell Earlywine, Understanding Marijuana: A New Look at the Scientific Evidence. New York: Oxford University Press, 2005. Kathleen J. Frydl, The Drug Wars in America, 1940–1973. New York: Cambridge University Press, 2013. Nunn, Kenneth B. (2002). "Race, Crime and the Pool of Surplus Criminality: Or Why the War on Drugs Was a War on Blacks". Gender, Race & Justice. 6 (6): 381. Tony Payan, "A War that Can't Be Won." Tucson: The University of Arizona Press, 2013. Preston Peet, Under the Influence: The Disinformation Guide to Drugs. The Disinformation Company, 2004. Thomas C.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.